Moment Of Truth For Belantamab Mafodotin, Trikafta And Turalio At EMA
Executive Summary
A number of drug companies are set to learn the fate of their marketing authorization applications in the EU this week.
You may also be interested in...
GSK's Belantamab Among Drugs Seeking EU Approval Nod
GlaxoSmithKline's potential multiple myeloma treatment is one of several new products that could get an EU marketing thumbs up from the European Medicines Agency this week.
Vertex's Triple CF Combo Gets EU Approval Nod; Rejection For Daiichi Sankyo
EU approval is likely for the eight medicines that got the thumbs up this week from the European Medicines Agency's drug evaluation committee, the CHMP. The panel held fire on one product it had been considering and also issued its first rejection of 2020.
Remdesivir Races Through EU Review
Gilead Sciences’ remdesivir could get the nod from the European Medicines Agency this week as a treatment for COVID-19, paving the way for swift EU approval.